Liu DH, Dong XM, Long WJ. Advancing cardiovascular outcomes with dapagliflozin and sacubitril in post-acute myocardial infarction heart failure and type 2 diabetes mellitus. World J Clin Cases 2024; 12(36): 6935-6938 [DOI: 10.12998/wjcc.v12.i36.6935]
Corresponding Author of This Article
Wen-Jie Long, MD, PhD, Doctor, Department of Geriatrics, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Guangzhou 510405, Guangdong Province, China. lwj5699@gzucm.edu.cn
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Dec 26, 2024; 12(36): 6935-6938 Published online Dec 26, 2024. doi: 10.12998/wjcc.v12.i36.6935
Advancing cardiovascular outcomes with dapagliflozin and sacubitril in post-acute myocardial infarction heart failure and type 2 diabetes mellitus
Dong-Hua Liu, Xiao-Ming Dong, Wen-Jie Long
Dong-Hua Liu, The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China
Xiao-Ming Dong, Wen-Jie Long, Department of Geriatrics, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China
Author contributions: Long WJ conceived the idea; Liu DH and Dong XM conducted a literature search; Liu DH wrote the preliminary draft; Dong XM and Long WJ critically reviewed as well as improved the manuscript; all authors have read and approved the final manuscript.
Supported bythe Scientific Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine, No. 2022ZYYJ01; and Guangzhou Municipal Science and Technology Bureau's 2024 Basic and Applied Basic Research Topic, No. 2024A04J4254.
Conflict-of-interest statement: There are no conflict-of-interest disclosures by any authors.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wen-Jie Long, MD, PhD, Doctor, Department of Geriatrics, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Guangzhou 510405, Guangdong Province, China. lwj5699@gzucm.edu.cn
Received: July 7, 2024 Revised: September 18, 2024 Accepted: October 22, 2024 Published online: December 26, 2024 Processing time: 115 Days and 14.4 Hours
Abstract
Coronary heart disease and type 2 diabetes mellitus (T2DM) often co-occur, presenting substantial health risks, particularly following acute myocardial infarction (AMI). While percutaneous coronary intervention (PCI) is a prevalent treatment, complications such as microvascular dysfunction may lead to heart failure, necessitating additional therapies. This editorial examines the emerging roles of sacubitril/valsartan and sodium-glucose co-transporter 2 inhibitors in managing post-PCI. Recent research investigates the combined effects of dapagliflozin and telmisartan on myocardial microperfusion in post-AMI heart failure patients with T2DM. The findings suggest that this combination enhances myocardial microcirculation, improves cardiac function, and achieves better glycemic control, with a reduced incidence of major adverse cardiovascular events. Despite ongoing challenges, the integration of dapagliflozin and sacubitril/valsartan represents a significant advancement in post-AMI care. Further investigation in larger cohorts and more diverse patient populations is required to confirm its long-term clinical outcomes.
Core Tip: This study highlights the combined use of dapagliflozin and sacubitril in patients with post-acute myocardial infarction heart failure and type 2 diabetes. The observed improvements in myocardial microcirculation, cardiac function, and glycemic control were significant, alongside a reduced incidence of major adverse cardiovascular events. The findings underscore the potential synergistic benefits of this therapeutic combination; however, long-term outcomes require further investigation. The results support the need for personalized treatment strategies to enhance cardiovascular care in this high-risk patient group.
